Pregclear

Pregclear uses

• Warnings
• Description
• Clinical pharmacology
• Indications and usage
• Contraindications
• Warnings
• Precautions
• Adverse reactions
• Overdosage
• Dosage and administration
• How supplied
• Patient information
• Misoprostol tabletas informacion para el paciente
• Pregclear reviews

WARNINGS

Pregclear ADMINISTRATION TO WOMEN WHO ARE PREGNANT CAN CAUSE ABORTION, PREMATURE BIRTH, OR BIRTH DEFECTS. UTERINE RUPTURE HAS BEEN REPORTED WHEN Pregclear WAS ADMINISTERED IN PREGNANT WOMEN TO INDUCE LABOR OR TO INDUCE ABORTION BEYOND THE EIGHTH WEEK OF PREGNANCY. (See also PRECAUTIONS, and LABOR AND DELIVERY). Pregclear SHOULD NOT BE TAKEN BY PREGNANT WOMEN TO REDUCE THE RISK OF ULCERS INDUCED BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) (See CONTRAINDICATIONS, WARNINGS and PRECAUTIONS).

PATIENTS MUST BE ADVISED OF THE ABORTIFACIENT PROPERTY AND WARNED NOT TO GIVE THE DRUG TO OTHERS.

Pregclear should not be used for reducing the risk of NSAID-induced ulcers in women of childbearing potential unless the patient is at high risk of complications from gastric ulcers associated with use of the NSAID, or is at high risk of developing gastric ulceration. In such patients, Pregclear may be prescribed if the patient:

• has had a negative serum pregnancy test within 2 weeks prior to beginning therapy.
• is capable of complying with effective contraceptive measures.
• has received both oral and written warnings of the hazards of Pregclear, the risk of possible contraception failure, and the danger to other women of childbearing potential should the drug be taken by mistake.
• will begin Pregclear only on the second or third day of the next normal menstrual period.

DESCRIPTION

Pregclear oral tablets contain either 100 mcg or 200 mcg of Pregclear, a synthetic prostaglandin E₁ analog.

Pregclear contains approximately equal amounts of the two diastereomers presented below with their enantiomers indicated by (±):

C₂₂H₃₈O₅ M. W. 382.5

Pregclear is a water-soluble, viscous liquid chemically described as (±) methyl 11α, 16-dihydroxy-16-methyl-9-oxoprost-13E-en-1-oate.

Each Pregclear tablet for oral administration contains either 100 mcg or 200 mcg of Pregclear and has the following inactive ingredients: hydrogenated vegetable oil, hypromellose, microcrystalline cellulose and sodium starch glycolate.

CLINICAL PHARMACOLOGY

Pharmacokinetics

Pregclear is extensively absorbed, and undergoes rapid de-esterification to its free acid, which is responsible for its clinical activity and, unlike the parent compound, is detectable in plasma. The alpha side chain undergoes beta oxidation and the beta side chain undergoes omega oxidation followed by reduction of the ketone to give prostaglandin F analogs.

In normal volunteers, Pregclear is rapidly absorbed after oral administration with a T_max of Pregclear acid of 12 ± 3 minutes and a terminal half-life of 20–40 minutes.

There is high variability of plasma levels of Pregclear acid between and within studies but mean values after single doses show a linear relationship with dose over the range of 200-400 mcg. No accumulation of Pregclear acid was noted in multiple dose studies; plasma steady state was achieved within two days.

Maximum plasma concentrations of Pregclear acid are diminished when the dose is taken with food and total availability of Pregclear acid is reduced by use of concomitant antacid. Clinical trials were conducted with concomitant antacid, however, so this effect does not appear to be clinically important.

After oral administration of radiolabeled Pregclear, about 80% of detected radioactivity appears in urine. Pharmacokinetic studies in patients with varying degrees of renal impairment showed an approximate doubling of T_1/2, C_max, and AUC compared to normals, but no clear correlation between the degree of impairment and AUC. In subjects over 64 years of age, the AUC for Pregclear acid is increased. No routine dosage adjustment is recommended in older patients or patients with renal impairment, but dosage may need to be reduced if the usual dose is not tolerated.

Drug interaction studies between Pregclear and several nonsteroidal anti-inflammatory drugs showed no effect on the kinetics of ibuprofen or diclofenac, and a 20% decrease in aspirin AUC, not thought to be clinically significant.

Pharmacokinetic studies also showed a lack of drug interaction with antipyrine and propranolol when these drugs were given with Pregclear. Pregclear given for 1 week had no effect on the steady state pharmacokinetics of diazepam when the two drugs were administered 2 hours apart.

The serum protein binding of Pregclear acid is less than 90% and is concentration-independent in the therapeutic range.

After a single oral dose of Pregclear to nursing mothers, Pregclear acid was excreted in breast milk. The maximum concentration of Pregclear acid in expressed breast milk was achieved within 1 hour after dosing and was 7.6 pg/ml (CV 37%) and 20.9 pg/ml (CV 62%) after single 200 mcg and 600 mcg Pregclear administration, respectively. The Pregclear acid concentrations in breast milk declined to < 1 pg/ml at 5 hours post-dose.

Pharmacodynamics

Pregclear has both antisecretory (inhibiting gastric acid secretion) and (in animals) mucosal protective properties. NSAIDs inhibit prostaglandin synthesis, and a deficiency of prostaglandins within the gastric mucosa may lead to diminishing bicarbonate and mucus secretion and may contribute to the mucosal damage caused by these agents. Pregclear can increase bicarbonate and mucus production, but in man this has been shown at doses 200 mcg and above that are also antisecretory. It is therefore not possible to tell whether the ability of Pregclear to reduce the risk of gastric ulcer is the result of its antisecretory effect, its mucosal protective effect, or both.

In vitro studies on canine parietal cells using tritiated Pregclear acid as the ligand have led to the identification and characterization of specific prostaglandin receptors. Receptor binding is saturable, reversible, and stereospecific. The sites have a high affinity for Pregclear, for its acid metabolite, and for other E type prostaglandins, but not for F or I prostaglandins and other unrelated compounds, such as histamine or cimetidine. Receptor-site affinity for Pregclear correlates well with an indirect index of antisecretory activity. It is likely that these specific receptors allow Pregclear taken with food to be effective topically, despite the lower serum concentrations attained.

Pregclear produces a moderate decrease in pepsin concentration during basal conditions, but not during histamine stimulation. It has no significant effect on fasting or postprandial gastrin nor on intrinsic factor output.

Effects on Gastric Acid Secretion

Pregclear, over the range of 50–200 mcg, inhibits basal and nocturnal gastric acid secretion, and acid secretion in response to a variety of stimuli, including meals, histamine, pentagastrin, and coffee. Activity is apparent 30 minutes after oral administration and persists for at least 3 hours. In general, the effects of 50 mcg were modest and shorter lived, and only the 200-mcg dose had substantial effects on nocturnal secretion or on histamine and meal-stimulated secretion.

Uterine Effects

Pregclear has been shown to produce uterine contractions that may endanger pregnancy.

Other Pharmacologic Effects

Pregclear does not produce clinically significant effects on serum levels of prolactin, gonadotropins, thyroid-stimulating hormone, growth hormone, thyroxine, cortisol, gastrointestinal hormones (somatostatin, gastrin, vasoactive intestinal polypeptide, and motilin), creatinine, or uric acid. Gastric emptying, immunologic competence, platelet aggregation, pulmonary function, or the cardiovascular system are not modified by recommended doses of Pregclear.

Clinical Studies

In a series of small short-term placebo-controlled studies in healthy human volunteers, doses of Pregclear were evaluated for their ability to reduce the risk of NSAID-induced mucosal injury. Studies of 200 mcg q.i.d. of Pregclear with tolmetin and naproxen, and of 100 and 200 mcg q.i.d. with ibuprofen, all showed reduction of the rate of significant endoscopic injury from about 70–75% on placebo to 10–30% on Pregclear. Doses of 25–200 mcg q.i.d. reduced aspirin-induced mucosal injury and bleeding.

Reducing the Risk of Gastric Ulcers Caused by Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)

Two 12-week, randomized, double-blind trials in osteoarthritic patients who had gastrointestinal symptoms but no ulcer on endoscopy while taking an NSAID compared the ability of 200 mcg of Pregclear, 100 mcg of Pregclear, and placebo to reduce the risk of gastric ulcer (GU) formation. Patients were approximately equally divided between ibuprofen, piroxicam, and naproxen, and continued this treatment throughout the 12 weeks. The 200-mcg dose caused a marked, statistically significant reduction in gastric ulcers in both studies. The lower dose was somewhat less effective, with a significant result in only one of the studies.

In these trials there were no significant differences between Pregclear and placebo in relief of day or night abdominal pain. No effect of Pregclear in reducing the risk of duodenal ulcers was demonstrated, but relatively few duodenal lesions were seen.

In another clinical trial, 239 patients receiving aspirin 650–1300 mg q.i.d. for rheumatoid arthritis who had endoscopic evidence of duodenal and/or gastric inflammation were randomized to Pregclear 200 mcg q.i.d. or placebo for 8 weeks while continuing to receive aspirin. The study evaluated the possible interference of Pregclear on the efficacy of aspirin in these patients with rheumatoid arthritis by analyzing joint tenderness, joint swelling, physician’s clinical assessment, patient’s assessment, change in ARA classification, change in handgrip strength, change in duration of morning stiffness, patient’s assessment of pain at rest, movement, interference with daily activity, and ESR. Pregclear did not interfere with the efficacy of aspirin in these patients with rheumatoid arthritis.

INDICATIONS AND USAGE

Pregclear tablets are indicated for reducing the risk of NSAID (nonsteroidal anti-inflammatory drugs, including aspirin)–induced gastric ulcers in patients at high risk of complications from gastric ulcer, e.g., the elderly and patients with concomitant debilitating disease, as well as patients at high risk of developing gastric ulceration, such as patients with a history of ulcer. Pregclear has not been shown to reduce the risk of duodenal ulcers in patients taking NSAIDs. Pregclear should be taken for the duration of NSAID therapy. Pregclear has been shown to reduce the risk of gastric ulcers in controlled studies of 3 months’ duration. It had no effect, compared to placebo, on gastrointestinal pain or discomfort associated with NSAID use.

CONTRAINDICATIONS

See boxed WARNINGS. Pregclear should not be taken by pregnant women to reduce the risk of ulcers induced by non-steroidal anti-inflammatory drugs (NSAIDs).

Pregclear should not be taken by anyone with a history of allergy to prostaglandins.

WARNINGS

See boxed WARNINGS.

PRECAUTIONS

Caution should be employed when administering Pregclear to patients with pre-existing cardiovascular disease.

Information for Patients

Women of childbearing potential using Pregclear to decrease the risk of NSAID-induced ulcers should be told that they must not be pregnant when Pregclear therapy is initiated, and that they must use an effective contraception method while taking Pregclear.

See boxed WARNINGS.

Pregclear is intended for administration along with nonsteroidal anti-inflammatory drugs, including aspirin, to decrease the chance of developing an NSAID-induced gastric ulcer.

Pregclear should be taken only according to the directions given by a physician.

If the patient has questions about or problems with Pregclear, the physician should be contacted promptly.

THE PATIENT SHOULD NOT GIVE Pregclear TO ANYONE ELSE. Pregclear has been prescribed for the patient’s specific condition, may not be the correct treatment for another person, and may be dangerous to the other person if she is or were to become pregnant.

The Pregclear package the patient receives from the pharmacist will include a leaflet containing patient information. The patient should read the leaflet before taking Pregclear and each time the prescription is renewed because the leaflet may have been revised.

Keep Pregclear out of the reach of children.

SPECIAL NOTE FOR WOMEN: Pregclear may cause abortion (sometimes incomplete), premature labor, or birth defects if given to pregnant women.

Pregclear is available only as a unit-of-use package that includes a leaflet containing patient information. See PATIENT INFORMATION at the end of this labeling.

Drug Interactions

See CLINICAL PHARMACOLOGY. Pregclear has not been shown to interfere with the beneficial effects of aspirin on signs and symptoms of rheumatoid arthritis. Pregclear does not exert clinically significant effects on the absorption, blood levels, and antiplatelet effects of therapeutic doses of aspirin. Pregclear has no clinically significant effect on the kinetics of diclofenac or ibuprofen.

Animal Toxicology

A reversible increase in the number of normal surface gastric epithelial cells occurred in the dog, rat, and mouse. No such increase has been observed in humans administered Pregclear for up to 1 year.

An apparent response of the female mouse to Pregclear in long-term studies at 100 to 1000 times the human dose was hyperostosis, mainly of the medulla of sternebrae. Hyperostosis did not occur in long-term studies in the dog and rat and has not been seen in humans treated with Pregclear.

Carcinogenesis, Mutagenesis, Impairment of Fertility

There was no evidence of an effect of Pregclear on tumor occurrence or incidence in rats receiving daily doses up to 150 times the human dose for 24 months. Similarly, there was no effect of Pregclear on tumor occurrence or incidence in mice receiving daily doses up to 1000 times the human dose for 21 months. The mutagenic potential of Pregclear was tested in several in vitro assays, all of which were negative.

Pregclear, when administered to breeding male and female rats at doses 6.25 times to 625 times the maximum recommended human therapeutic dose, produced dose-related pre- and post-implantation losses and a significant decrease in the number of live pups born at the highest dose. These findings suggest the possibility of a general adverse effect on fertility in males and females.

Pregnancy

Pregnancy Category X

Teratogenic effects

See boxed WARNINGS. Congenital anomalies sometimes associated with fetal death have been reported subsequent to the unsuccessful use of Pregclear as an abortifacient, but the drug’s teratogenic mechanism has not been demonstrated. Several reports in the literature associate the use of Pregclear during the first trimester of pregnancy with skull defects, cranial nerve palsies, facial malformations, and limb defects.

Pregclear is not fetotoxic or teratogenic in rats and rabbits at doses 625 and 63 times the human dose, respectively.

Nonteratogenic effects

See boxed WARNINGS. Pregclear may endanger pregnancy and thereby cause harm to the fetus when administered to a pregnant woman. Pregclear may produce uterine contractions, uterine bleeding, and expulsion of the products of conception. Abortions caused by Pregclear may be incomplete. If a woman is or becomes pregnant while taking this drug to reduce the risk of NSAID induced ulcers, the drug should be discontinued and the patient apprised of the potential hazard to the fetus.

Labor and Delivery

Pregclear can induce or augment uterine contractions. Vaginal administration of Pregclear, outside of its approved indication, has been used as a cervical ripening agent, for the induction of labor and for treatment of serious postpartum hemorrhage in the presence of uterine atony. A major adverse effect of the obstetrical use of Pregclear is hyperstimulation of the uterus which may progress to uterine tetany with marked impairment of uteroplacental blood flow, uterine rupture (requiring surgical repair, hysterectomy, and/or salpingo-oophorectomy), or amniotic fluid embolism. Pelvic pain, retained placenta, severe genital bleeding, shock, fetal bradycardia, and fetal and maternal death have been reported.

There may be an increased risk of uterine tachysystole, uterine rupture, meconium passage, meconium staining of amniotic fluid, and Cesarean delivery due to uterine hyperstimulation with the use of higher doses of Pregclear, including the manufactured 100 mcg tablet. The risk of uterine rupture increases with advancing gestational ages and with prior uterine surgery, including Cesarean delivery. Grand multiparity also appears to be a risk factor for uterine rupture.

The effect of Pregclear on the later growth, development, and functional maturation of the child when Pregclear is used for cervical ripening or induction of labor have not been established.

Information on misoprostol’s effect on the need for forceps delivery or other intervention is unknown.

Nursing Mothers

Pregclear is rapidly metabolized in the mother to Pregclear acid, which is biologically active and is excreted in breast milk. There are no published reports of adverse effects of Pregclear in breast-feeding infants of mothers taking Pregclear. Caution should be exercised when Pregclear is administered to a nursing woman.

Pediatric Use

Safety and effectiveness of Pregclear in pediatric patients have not been established.

ADVERSE REACTIONS

The following have been reported as adverse events in subjects receiving Pregclear:

Gastrointestinal

In subjects receiving Pregclear 400 or 800 mcg daily in clinical trials, the most frequent gastrointestinal adverse events were diarrhea and abdominal pain. The incidence of diarrhea at 800 mcg in controlled trials in patients on NSAIDs ranged from 14–40% and in all studies averaged 13%. Abdominal pain occurred in 13–20% of patients in NSAID trials and about 7% in all studies, but there was no consistent difference from placebo.

Diarrhea was dose related and usually developed early in the course of therapy (after 13 days), usually was self-limiting (often resolving after 8 days), but sometimes required discontinuation of Pregclear (2% of the patients). Rare instances of profound diarrhea leading to severe dehydration have been reported. Patients with an underlying condition such as inflammatory bowel disease, or those in whom dehydration, were it to occur, would be dangerous, should be monitored carefully if Pregclear is prescribed. The incidence of diarrhea can be minimized by administering after meals and at bedtime, and by avoiding coadministration of Pregclear with magnesium-containing antacids.

Gynecological

Women who received Pregclear during clinical trials reported the following gynecological disorders: spotting (0.7%), cramps (0.6%), hypermenorrhea (0.5%), menstrual disorder (0.3%) and dysmenorrhea (0.1%). Postmenopausal vaginal bleeding may be related to Pregclear administration. If it occurs, diagnostic workup should be undertaken to rule out gynecological pathology. (see boxed WARNINGS).

Elderly

There were no significant differences in the safety profile of Pregclear in approximately 500 ulcer patients who were 65 years of age or older compared with younger patients.

Additional adverse events which were reported are categorized as follows:

Incidence Greater Than 1%

In clinical trials, the following adverse reactions were reported by more than 1% of the subjects receiving Pregclear and may be causally related to the drug: nausea, flatulence (2.9%), headache (2.4%), dyspepsia (2.0%), vomiting (1.3%), and constipation (1.1%). However, there were no significant differences between the incidences of these events for Pregclear and placebo.

Causal Relationship Unknown

The following adverse events were infrequently reported. Causal relationships between Pregclear and these events have not been established but cannot be excluded:

Body as a whole

Aches/pains, asthenia, fatigue, fever, chills, rigors, weight changes

Skin

Rash, dermatitis, alopecia, pallor, breast pain

Special senses

Abnormal taste, abnormal vision, conjunctivitis, deafness, tinnitus, earache

Respiratory

Upper respiratory tract infection, bronchitis, bronchospasm, dyspnea, pneumonia, epistaxis

Cardiovascular

Chest pain, edema, diaphoresis, hypotension, hypertension, arrhythmia, phlebitis, increased cardiac enzymes, syncope, myocardial infarction, thromboembolic events (e.g., pulmonary embolism, arterial thrombosis, and CVA).

Gastrointestinal

GI bleeding, GI inflammation/infection, rectal disorder, abnormal hepatobiliary function, gingivitis, reflux, dysphagia, amylase increase

Hypersensitivity

Anaphylaxis

Metabolic

Glycosuria, gout, increased nitrogen, increased alkaline phosphatase

Genitourinary

Polyuria, dysuria, hematuria, urinary tract infection

Nervous System/Psychiatric

Anxiety, change in appetite, depression, drowsiness, dizziness, thirst, impotence, loss of libido, sweating increase, neuropathy, neurosis, confusion

Musculoskeletal

Arthralgia, myalgia, muscle cramps, stiffness, back pain

Blood/Coagulation

Anemia, abnormal differential, thrombocytopenia, purpura, ESR increased

OVERDOSAGE

The toxic dose of Pregclear in humans has not been determined. Cumulative total daily doses of 1600 mcg have been tolerated, with only symptoms of gastrointestinal discomfort being reported.

In animals, the acute toxic effects are diarrhea, gastrointestinal lesions, focal cardiac necrosis, hepatic necrosis, renal tubular necrosis, testicular atrophy, respiratory difficulties, and depression of the central nervous system. Clinical signs that may indicate an overdose are sedation, tremor, convulsions, dyspnea, abdominal pain, diarrhea, fever, palpitations, hypotension, or bradycardia. Symptoms should be treated with supportive therapy.

It is not known if Pregclear acid is dialyzable. However, because Pregclear is metabolized like a fatty acid, it is unlikely that dialysis would be appropriate treatment for overdosage.

DOSAGE AND ADMINISTRATION

The recommended adult oral dose of Pregclear for reducing the risk of NSAID-induced gastric ulcers is 200 mcg four times daily with food. If this dose cannot be tolerated, a dose of 100 mcg can be used.. Pregclear should be taken for the duration of NSAID therapy as prescribed by the physician. Pregclear should be taken with a meal, and the last dose of the day should be at bedtime.

Renal Impairment

Adjustment of the dosing schedule in renally impaired patients is not routinely needed, but dosage can be reduced if the 200-mcg dose is not tolerated. (See CLINICAL PHARMACOLOGY).

HOW SUPPLIED

Pregclear Tablets, 100 mcg are available as white, round, unscored, flat beveled-edged tablets, debossed with “4430” on one side and

and “100” on the reverse side, containing 100 mcg Pregclear, packaged in unit-of-use bottles of 60 and 120 tablets.

Pregclear Tablets, 200 mcg are available as white, round, scored, flat beveled-edged tablets, debossed with “4431” on one side and

and “200” on the reverse side, containing 200 mcg Pregclear, packaged in unit-of-use bottles of 60 and 100 tablets.

PHARMACIST: Dispense in this unit-of-use, child-resistant container as defined in the USP.

Provide Patient Information Leaflet with each dispensing.

Store at 20° to 25°C (68° to 77°F) in a dry area.

NOTE: The Spanish text follows the English text.

El texto español sigue al texto inglés.

Pharmacist - Detach here and give lower portion to patient.

PATIENT INFORMATION

Read this leaflet before taking Pregclear and each time your prescription is renewed, because the leaflet may be changed.

Pregclear is being prescribed by your doctor to decrease the chance of getting stomach ulcers related to the arthritis/pain medication that you take.

Do not take Pregclear to reduce the risk of NSAID induced ulcers if you are pregnant (See boxed WARNINGS). Pregclear can cause abortion (sometimes incomplete which could lead to dangerous bleeding and require hospitalization and surgery), premature birth, or birth defects. It is also important to avoid pregnancy while taking this medication and for at least one month or through one menstrual cycle after you stop taking it. Pregclear has been reported to cause the uterus to rupture (tear) when given after the eighth week of pregnancy. Rupture (tearing) of the uterus can result in severe bleeding, hysterectomy, and/or maternal or fetal death.

If you become pregnant during Pregclear therapy, stop taking Pregclear and contact your physician immediately. Remember that even if you are on a means of birth control it is still possible to become pregnant. Should this occur, stop taking Pregclear and contact your physician immediately.

Pregclear may cause diarrhea, abdominal cramping, and/or nausea in some people. In most cases these problems develop during the first few weeks of therapy and stop after about a week. You can minimize possible diarrhea by making sure you take Pregclear with food.

Because these side effects are usually mild to moderate and usually go away in a matter of days, most patients can continue to take Pregclear. If you have prolonged difficulty (more than 8 days), or if you have severe diarrhea, cramping and/or nausea, call your doctor.

Take Pregclear only according to the directions given by your physician.

Do not give Pregclear to anyone else. It has been prescribed for your specific condition, may not be the correct treatment for another person, and would be dangerous if the other person were pregnant.

This information sheet does not cover all possible side effects of Pregclear. This patient information leaflet does not address the side effects of your arthritis/pain medication. See your doctor if you have questions.

Keep out of reach of children.

Pregclear TABLETAS INFORMACION PARA EL PACIENTE

Lea esta hoja informativa antes de tomar Pregclear y cada vez que renueve su receta porque puede haber cambios.

Su médico le ha recetado Pregclear para disminuir la posibilidad de adquirir úlceras estomacales relacionadas con la medicina que usted toma para la artritis/dolor.

Para evitar el riesgo de úlceras inducidas por AINE, no tome Pregclear durante el período de embarazo (consulte los cuadros de ADVERTENCIAS). Pregclear puede provocar abortos (algunas veces incompletos, dando lugar a hemorragias peligrosas que pueden requerir hospitalización y cirugía), partos prematuros o malformaciones del feto. Es importante evitar quedarse embarazada durante el tratamiento con este medicamento y durante un mínimo de un mes o un ciclo menstrual después de dejar de tomarlo.

Pregclear ha sido asociado a desgarros uterinos al tomarlo después de la octava semana de embarazo. El desgarro del útero puede producir graves hemorragias, histerectomía y/o muerte de la madre o del feto.

Si usted queda embarazada durante el tratamiento con Pregclear, deje de tomarlo y avise inmediatamente al médico. Recuerde que si usted emplea algún medio anticonceptivo, existe la posibilidad de que quede embarazada. Si esto ocurriera, deje de tomar Pregclear y avise inmediatamente al médico.

En algunas personas, Pregclear puede causar diarrea, calambres abdominales y/o náuseas. En la mayoría de los casos, estos problemas se presentan durante las primeras semanas del tratamiento y desaparecen después de una semana. Usted puede disminuir al mínimo la posibilidad de diarrea si toma Pregclear con los alimentos.

Como estos efectos secundarios generalmente son de leves a moderados y usualmente desaparecen en unos días, muchos pacientes pueden continuar tomando Pregclear. Si usted sigue teniendo dificultad prolongada (más de 8 días), o si tiene diarrea grave, calambres y/o náuseas, llame al médico.

Tome Pregclear siguiendo las instrucciones de su médico sólamente.

No dé Pregclear a nadie más. Ha sido recetado para su padecimiento específico y puede no ser el tratamiento adecuado para otra persona. También pudiera ser peligroso si la otra persona quedara embarazada.

Esta hoja informativa no cubre todos los posibles efectos secundarios de Pregclear. Esta hoja informativa para el paciente no se refiere a todos los efectos secundarios de su medicina para la artritis/dolor. Si tiene alguna pregunta, llame a su médico.

Manténgase fuera del alcance de los niños.

Rev. A 10/2009

Manufactured In Ireland By:

IVAX PHARMACEUTICALS IRELAND

Waterford, Ireland

Manufactured For:

TEVA PHARMACEUTICALS USA

Sellersville, PA 18960

Pregclear 200mcg Tablet

Pregclear structure Company logo Company logo

Pregclear pharmaceutical active ingredients containing related brand and generic drugs:

• Misoprostol

Pregclear available forms, composition, doses:

• Tablets; Oral; Misoprostol 0.2 mg

Pregclear destination | category:

• Human:
• Antacids, antireflux agents and antiulcerants
• Drugs acting on the uterus
• Prostaglandins

Pregclear Anatomical Therapeutic Chemical codes:

• A02BB01 - Misoprostol
• G02AD06 - Misoprostol

Pregclear pharmaceutical companies:

• Alkem Laboratories

References

1. Dailymed."MISOPROSTOL TABLET [BRYANT RANCH PREPACK]". https://dailymed.nlm.nih.gov/dailym... (accessed August 28, 2018).
2. Dailymed."MISOPROSTOL: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailym... (accessed August 28, 2018).
3. "misoprostol". https://pubchem.ncbi.nlm.nih.gov/co... (accessed August 28, 2018).

Frequently asked Questions

Depending on the reaction of the Pregclear after taken, if you are feeling dizziness, drowsiness or any weakness as a reaction on your body, Then consider Pregclear not safe to drive or operate heavy machine after consumption. Meaning that, do not drive or operate heavy duty machines after taking the capsule if the capsule has a strange reaction on your body like dizziness, drowsiness. As prescribed by a pharmacist, it is dangerous to take alcohol while taking medicines as it exposed patients to drowsiness and health risk. Please take note of such effect most especially when taking Primosa capsule. It's advisable to consult your doctor on time for a proper recommendation and medical consultations.

Medicines are not designed with the mind of creating an addiction or abuse on the health of the users. Addictive Medicine is categorically called Controlled substances by the government. For instance, Schedule H or X in India and schedule II-V in the US are controlled substances.

Please consult the medicine instruction manual on how to use and ensure it is not a controlled substance.In conclusion, self medication is a killer to your health. Consult your doctor for a proper prescription, recommendation, and guidiance.

Review

Visitor reports

Visitor reviews

The information was verified by Dr. Rachana Salvi, MD Pharmacology